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Introduction
Meningococcal invasive disease is a life-threatening 
infection that affects mostly children and adolescents 
worldwide. It is estimated that around 500,000 cases 
and 50,000 deaths occur annually worldwide [1]. The 
case-fatality rate is 7.78% in Europe and 10-14% in the 
USA, and serious sequelae, including deafness, neuro-
logical problems and amputations are possible among 
survivors [2, 3].
Historical overview of the epidemiology  
of N. meningitidis in Italy
Before 1987 the incidence of meningococcal cases in 
Italy was over 1/100,000 and has stabilized at around 
0.6/100,000 in 1987 [4]. The highest number of cases 
in 1987 was seen in the 1-4 year-old age group (27%). 
The highest percentage of the isolates (63%) belonged 
to serogroup C while 25% belonged to serogroup B [5]. 
Between 1985 and 1989 in Italy N. meningitidis sero-
group C dominated. The incidence rate at the end of 
the Eighties was 0.5/100,000 in the general population. 
The highest proportion of cases (27%) was seen in sub-
jects 5-14 years old. Forty-four percent of the isolates 
belonged to serogroup B while 37% belonged to group 
C [6]. In 1990 a predominance of serogroup B was re-
vealed (72% of the isolates) while 12% belonged to 
group C. The highest proportion of cases (32%) was 
observed in subjects 1-4 years old [7]. In 1994, 603 
cases of bacterial meningitis were reported in Italy one 
third of which were due to N. meningitidis (33.4%) and 
occurred in subjects below five years of age (35.7%). 
The estimated incidence of N. meningitidis in Italy 
was 0.27/100,000. Serogroup B accounted for 62.5% 
of the serotyped isolates, group C for 23.1%, group A 
for 7.2%, group W-135 for 3.6%, group Y for 1.8% [8] 
During 1999-2001, the average incidence was 0.4 cases 
per 100,000 inhabitants. Serogroup B was predominant 
and accounted for 75% of the isolates, followed by se-
rogroup C with 24% [9]. 
In Italy, each year about 900 cases of bacterial menin-
gitis occur, one third are caused by N. meningitidis, one 
third by S. pneumoniae, while in the remaining cases ei-
ther the cause is represented by different bacteria or it 
remains unknown.
Available vaccines against N. meningitidis
Five major groups of N. meningitidis (A, B, C, Y and 
W135) are responsible for most meningococcal dis-
eases. Vaccination is the main tool in the fight against 
meningococcal meningitis. Infections caused by sero-
groups A, C, Y and W135 can be prevented by poly-
saccharide vaccines, which however are not effective 
in younger children, especially under 2 years of age, 
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Summary
Background. In Italy one third of bacterial meningitis are caused 
by Neisseria meningitidis. In March 2005, the Regional Health 
Authority of Tuscany included the meningococcal serogroup C 
conjugate (MCC) vaccine in the recommended vaccination pro-
gram with a schedule of three doses to all newborns at 3, 5 and 13 
months of age (from 2008 amended to a single dose at 13 months) 
and a single catch-up dose until age 6. 
Objective. To evaluate the impact of the current national and 
regional immunization strategies against N. meningitidis and to 
highlight new perspectives for meningococcal disease prevention 
with the existing tetravalent meningococcal vaccine (ACWY) and 
with the future incoming meningococcal B vaccines. 
Methods. Meningitis incidence rates in Italy and in Tuscany were 
calculated for the period 1994-2011 and 2005-2011,respectively. 
Immunization coverage with MCC vaccine in Tuscany and vacci-
nation status of meningitis cases were reported. Literature review 
on meningococcal conjugate vaccine use and recommendation 
was performed. 
Results. A decrease in incidence rates of meningococcal menin-
gitis was observed in all age groups involved in the immunization 
campaign. Immunization coverage with MCC increased progres-
sively year by year in Tuscany. A herd immunity effect was meas-
ured in unvaccinated age groups. Since 2006 no cases of invasive 
meningococcal C infection in vaccinated subjects were observed 
in Tuscany. 
Conclusions. Implementation of MCC vaccination in Tuscany 
was effective in preventing meningococcal C disease, confirming 
the effectiveness of the vaccine. A new tetravalent (ACWY) con-
jugate vaccine is now available and its use in all Italian Regions 
should be considered.
The full article is free available on www.jpmh.org
a. BeChiNi et al.
62
in whom a T-cell dependent immunity is not induced 
and a long-term immunological memory cannot be 
elicited. 
Currently conjugate vaccines for the prevention of N. 
meningitidis serotype C infection are available. MCC 
vaccines were developed in the late 1990s, after the suc-
cessful experience with Haemophilus influenzae and 
pneumococcal conjugate vaccines [10]. United King-
dom was the first country to introduce the vaccination 
in 1999 [11]. Due to the success of the immunization 
programme, in 2000 the vaccine was also introduced 
into national publicly funded routine immunization 
programmes in Ireland and Spain; in 2002 in Iceland, 
in Belgium and in the Netherlands; in 2006 in Portugal, 
Greece and Germany [12].
Vaccination strategies in Italy and Tuscany
In Italy the Ministry of Health entitles Regions and Au-
tonomous Provinces to implement different meningococ-
cal vaccination policies according to the local epidemiol-
ogy and priorities. In the Italian National Vaccine Plan 
2012-2014 MCC vaccination was recommended for in-
fants between 13 and 15 months of age and for adoles-
cents (11-18 years) [13]. Since 2003, the MCC vaccine in 
Tuscany was offered to subjects at risk in all age groups 
and it was accessible to all subjects in co-payment.
Tuscany was the first Region to approve and include the 
conjugate meningococcus C (MCC) vaccination in the 
recommended vaccination program with a schedule of 
three doses to all newborns at 3, 5 and 13 months of age 
(from 2008 amended to a single dose at 13 months) and 
a single catch-up dose until age 6 [14]. 
Recently (March 2010), a quadrivalent conjugate vac-
cine against serogroups A, C, Y, W-135, was authorized 
in European Union and it is now indicated for active 
immunisation of children (from 2 years of age), adoles-
cents and adults at risk of exposure to Neisseria menin-
gitidis groups A, C, W135 and Y, to prevent invasive 
disease [15]. 
The purpose of this study was to evaluate the impact 
of the current national and regional immunization 
strategies against N. meningitidis and to highlight new 
perspectives for meningococcal disease prevention 
with the existing tetravalent meningococcal vaccine 
(ACWY) and with the future incoming meningococcal 
B vaccines.
Methods
Data collection
Data collection started in 2009 and ended in February 
2012. The Regional Health Authority provided surveil-
lance data on IBD:
•	 notification	 of	 meningitis	 cases	 by	 etiologic	 agent	
and year of notification
•	 immunization	coverage	at	24	months	of	age,	by	birth	
cohort.
Incidence rates were calculated by age groups: < 1 year; 
1-4 years; 5-14 years; 15-20 years; 21-30 years; 31-49 
years; 50-64 years; ≥ 65 years.
In order to calculate incidence data for meningitis cas-
es the number of notified cases in Tuscany was divid-
ed by the resident Tuscan population in the same age 
groups [16].
Italian surveillance data were obtained by means of the 
SIMI (Infectious Diseases Information System) data-
base and incidence rates were calculated on the resident 
Italian population [17].
The SIMI provides passive notification data; it is based 
on the notifications filled by the local public health units 
on the basis of the medical reports received. To calcu-
late the vaccination coverage, the number of vaccinated 
children (numerator) was derived from the coverage da-
tabase of the 12 regional local health care units, whereas 
the total number of children eligible for vaccination in 
each age group (denominator), was obtained from the 
census data from the same areas.
Fig. 1. Cases of N. meningitidis by serogroup B and C in italy, by year (2001-2011*) (*) data for 
2011 are updated to 24 February 2012.
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Results
Italy and Tuscany
In Italy a shift in prevalence from serogroup C to se-
rogroup B isolates was observed during the Nineties 
and up to 2003. In the years 2004 and 2005 isolates 
of serogroup C have exceeded those of serogroup B 
(Fig. 1). 
The proportion of serogroup C isolates was over 50% 
for both 2004 and 2005 and decreased to about 20% in 
2011 (Tab. I).
Since 2006 the annual number of N. meningitidis cases 
has remained under 200 ranging between 141 and 187 
cases corresponding to incidence values between 0.31 
and 0.23 (Fig. 2) [17]. 
The highest incidence rates of meningitis cases due to any 
causal agents in Tuscany from 2005 to 2011 were cal-
culated in infants, ranging from 3.2/100.000 in 2005 to 
9.3/100.000 in 2010. An incidence rate of 5.1/100.000 
Fig. 3. Cases of N. meningitidis by serogroup B and C in tuscany, by year (2001-2011*) (*) data for 
2011 are updated to January 2012).
Fig. 2. incidence of meningitis cases in italy, by year (2005 – 2011*). (*) data of 2011 are provisional 
and updated to February 2012. [17] population data source: [16].
was registered in subjects of 
1-4 years in 2005, a value that 
gradually decreased the follow-
ing three years but increased in 
2009 and in 2010, still remaining 
lower than in 2005 (3.9/100.000 
and 2.3/100.000, respectively). 
As far as subjects aged 5-14 
years are concerned, the high-
est incidence rate was reached in 
2005 (2.1/100.000), and became 
around 1/100.000 in 2010 and 
1.6/100.000 in 2011.
The incidence rate in sub-
jects of 15-20 years was nearly 
1.7/100.000 between 2005 and 
2009. In 2011 it was 0.5/100.000. 
No cases were registered in 
2010. In subjects older than 20 
a decrease in meningitis C inci-
dence was registered in the pe-
riod of observation. 
All serogroup C cases observed 
since 2006 occurred in unvacci-
nated subjects.
Immunization coverage at 24 
months of age with MCC in-
creased progressively year by 
year in Tuscany. During the six-
year period it improved from 
68% in 2006 to 90.5% in 2011. 
Results are reported in Table II.
Tab. I. proportion of meningitis caused by serogroups C on the total 
of N. meningitidis isolates in italy, by year (2991-2011*) (*) data of 
2011 are provisional and updated to February 2012.
Neisseria 
meningitidis 
serogroup C
total  
isolated 
meningococci
Percentage of C/
(C+B+unidentified)
2001 22 88 25,0
2002 46 113 40,7
2003 67 157 42,7
2004 102 178 57,3
2005 115 208 55,3
2006 39 116 33,6
2007 43 124 34,7
2008 55 133 41,4
2009 46 138 33,3
2010 21 95 22,1
2011* 17 89 19,1
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The immunization coverage with MCC vaccine by 
birth cohort ranged from 49% to 68% (average 58.1%) 
in 2006, for the cohort of subjects born in 2001 and in 
2004, respectively and it ranged from 61% to 87% (av-
erage 75.3%) in 2009, for the cohort of subjects born in 
2000 and in 2006, respectively (Tab. III).
The catch-up immunization of children under 6 years in 
Tuscany allowed to increase immunization coverage in 
four years (2006-2009) by a minimum of 11%, for sub-
jects born in 2000 and in 2003, to a maximum of 23% for 
children born in 2005 and 2006. The highest immuniza-
tion coverage values are registered in younger children.
Discussion and conclusions
In Italy the number of serogroup C meningococcal cases 
decrease gradually after the introduction of the MCC 
vaccine. 
According to ICONA 2008 survey in Tuscany immuni-
zation coverage with MCC vaccine at 24 months of age 
was 64.3% (IC95%: 55.6% -73.0%), which is lower than 
the official routine immunization coverage reported in 
this study (Tab. II). In Italy, immunization coverage with 
MCC vaccine are very low in children at 24 months of 
age (36.9%). Children immunized with a cycle of three 
doses in the first year of life were 5.6%, while 31.3% 
received one dose in the second year of life. Immuni-
zation coverage for children “at risk” was 29.9%. ICO-
NA survey reported a value of 21.4% (IC95%: 14.7%-
28.1%), for Tuscan adolescents (16 years old) which is 
higher than the Italian adolescents immunization cover-
age (16.0%; IC95%:14.2%-17.8%). As far as concern 
MCC vaccination coverage in Italy there is generally a 
high regional variability: five regions reported an im-
munization coverage between 20 and 72%, while in all 
the other regions the coverage is lower than 10%. As 
long as MCC vaccine will be underused in Italy, cases 
of meningitis will continue to occur and incidence rates 
will maintain high, especially in those age groups more 
affected by the disease [18].
Fig. 4. Cases of N. meningitidis serogroup C in tuscany by age group and vaccination status (2005-2011*). (*) data for 2011 are updated to 
January 2012.
Tab. II. vaccination coverage with mCC vaccine at 24 months of age 
(%) in tuscany, 2006-2011.
Year
Vaccination coverage at 24 months 
of age (%)
2006 67.9
2007 72.8
2008 83.8
2009 87.2
2010 88
2011 90.5
Tab. III. vaccination coverage with men C vaccine in tuscany, by birth 
cohort (2006-2009).
2006
(%)
2007
(%)
2008
(%)
2009
(%)
Born in 2000 50.3 55.5 59.5 61.3
Born in 2001 48.7 59.2 63.8 65.0
Born in 2002 54.4 63.1 69.7 72.0
Born in 2003 64.4 69.2 74.0 75.6
Born in 2004 67.9 73.3 78.3 80.4
Born in 2005 63.1 72.8 84.0 85.2
Born in 2006 64.7 83.8 87.2
average 58.1 65.4 73.3 75.3
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Invasive Meningococcal Disease (IMD) cases in 2005 
and 2008 reported to the National Meningococcal Sur-
veillance System showed an incidence of 0.5 and 0.3 per 
100,000 inhabitants, respectively. While the incidence 
due to serogroup B continued to be stable, IMD inci-
dence due to serogroup C has decreased since 2006, par-
ticularly among infants [19].
The incidence rate of meningococcal disease in Italy 
is currently among the lowest in Europe with 200-300 
cases per year (0.25/100,000 in 2010) [20]. In Tuscany 
the proportion of serogroup C isolates represented about 
20% of meningococcal cases in 2011. A constant de-
crease of Men C cases was observed after the introduc-
tion of MCC vaccination.
In Italy, as in Tuscany, an increase in the isolation of 
serogroup Y and sporadic isolation of serogroup W-135 
was observed since 2001.
Variations over time of meningococcal serogroups were 
observed in many countries. From the mid-90s, sero-
group Y has spread in the United States to become the 
predominant serogroup in 2007 (Y: 37%; C: 29%; B: 
25% and W-135: 9%). From 1998 to 2006 the percent-
age of N. meningitidis serogroup Y isolated from pa-
tients with IMD in Italy has increased. Before 2005 the 
proportion of serogroup Y isolates ranged between 0 and 
4% of the total strains sent to the National Reference 
Laboratory (NRL) at the Istituto Superiore di Sanità, but 
an increase up to 7% was observed during 2006. Mo-
lecular characteristics of invasive serogroup Y in Italy 
will be helpful to monitor the spread of this serogroup in 
the next years [21].
Serogroup W-135 has begun to be present in significant 
percentage worldwide. The origin of the spread of N. 
meningitidis serogroup W-135 began in Saudi Arabia 
with the pilgrimage to Mecca in 2000. A spread in Afri-
ca and globally with the return of pilgrims was observed 
in the following period. Recently W-135 has become 
endemic in South Africa and has spread from Africa to 
Europe, Asia and North America [22-24].
N. meningitidis bacteria are characterized by a dynamic 
epidemiology whose determinants are: recombination 
between different serogroups, through genetically deter-
mined mechanisms and international travels, which pro-
mote the spread of different serotypes [25, 26]. These 
two factors contribute to determine an unpredictable 
epidemiology.
During 2003-2005 a study was performed in Italy to com-
pare the phenotypic characteristics of meningococcal iso-
lates from the two age groups most at risk of developing 
invasive meningococcal disease (children aged <4 years 
and adolescents aged 15-19 years) with those from other 
age groups in order to assess whether strategies for treat-
ment and prevention implemented elsewhere can also be 
applied in Italy. Serogroup C was found to have replaced 
serogroup B as the predominant serogroup since 2004. A 
dramatic increase, from 50.9% to 87.4%, in the circulation 
of strains with decreased susceptibility to penicillin was 
observed especially among serogroup C isolates, without 
great differences in terms of distribution among the differ-
ent age groups. In contrast, a greater percentage of sero-
group B isolates with reduced susceptibility to penicillin 
was isolated from children and adolescents than from oth-
er age groups. The circulation of meningococci with de-
creased susceptibility to penicillin needs continuous moni-
toring in order to determine vaccination strategies [27].
A strong correlation between the serum bactericidal an-
tibodies and antibodies to the polysaccharide capsule of 
C exists. A seroepidemiological study was performed in 
Italy in 2003-2004 and a total of 577 sera were collected 
in 17 of the 20 Italian Regions. The geometric mean 
titre of bactericidal antibodies (SBA GMT) was low in 
subjects under 1 year of age, significantly increased in 
1-9-year-old children and decreased in adolescents and 
young adults. According to this survey meningococcus 
C has the highest probability of spreading among 1-4, 
8-10 and 14-17-year-old subjects in Italy [28].
Besides, studies of meningococcal carriage are a good 
tool in improving knowledge on the epidemiology of 
meningococcal disease. In a sample of students from the 
University of Bari the circulation of N. meningitidis was 
investigated. The nasopharyngeal swabs of 583 universi-
ty students were collected and 12 carriers were identified 
(2%). Nine isolates proved auto-agglutinable, the other 
strains belonged to serogroups B, W135 and Y. No type C 
serogroup strain was detected and this could be right asso-
ciated to immunization policies providing meningococcal 
serogroup C conjugate vaccines for newborns and ado-
lescents in Puglia. The shifting pattern of N. meningitidis 
serogroups circulating in healthy carriers could support 
the adoption of quadrivalent meningococcal conjugate 
vaccines to pre-adolescents and adults [29].
After MCC vaccine introduction in infants and adoles-
cents, meningococcus serogroup B have been responsible 
of most cases of IMD in Italy. MenB vaccines can con-
tribute to containing meningococcal disease. There is still 
no universal vaccine available against the serogroup B, 
which is a major cause of invasive disease [30]. The de-
velopment of MenB vaccines has focused on subcapsular 
antigens as outer membrane vesicles (OMVs) [31]. Sev-
eral candidate OMV vaccines have been tested in large-
scale efficacy studies in Norway, Cuba, Brazil, Chile and 
New Zealand. Protection rate of 57.2% was observed in 
Norwegian secondary school students, but in other coun-
tries a variation in estimated vaccine efficacy by age was 
observed [32, 33]. The serum bactericidal antibody (SBA) 
titres of sera collected from toddlers and school children, 
pre- and post-vaccination, with a hexavalent OMV vac-
cine has been evaluated in phase I and II trials with prom-
ising results. The numbers of subjects with SBA titres of 
< 4, 4 and > or = 8 varied greatly between the different 
strains. On the basis of genotypic data and potential cross-
reactivity, the MenB vaccine has the potential to protect 
against a significant proportion of MenB disease in Eng-
land and Wales [34]. On the other hand, none of the sub-
types included in the hexavalent outer membrane vesicle 
(OMV) vaccine that is currently being evaluated in the 
UK [31] was significantly represented among group B 
isolates circulating in Italy [27].
Another approach to develop MenB vaccines is “reverse 
vaccinology” which consists in the use of genomics for 
vaccine development. More than 600 universal, cross-reac-
a. BeChiNi et al.
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tive antigens have been identified sequencing the genome 
of N. meningitidis through “reverse vaccinology” and suc-
cessfully tested as recombinant protein vaccines [33, 35].
What is the possible integration of a Men B 
vaccine in the Italian calendar?
The vaccine in a more advanced stage of testing (ear-
ly stage 3) is currently assessed under schedule 2, 4, 6 
months and 2, 3, 4 months. There will be a likely future 
trial with schedule 3, 5, 12 months. But the insertion of 
this new vaccine may result in two risks (1) a drop of 
vaccine coverage for all vaccines in case of the introduc-
tion of new appointments in the first year of life, (2) lack 
of acceptance by parents in case of return to 3 injections 
per session (hexavalent, pneumococcal conjugate and 
meningo B vaccines).
Given all experience gained in this field, the develop-
ment of a universal vaccine for prevention of group B 
meningococcal disease looks promising. Selection of 
strains representative of the global epidemiological situ-
ation will be of outmost importance, defining criteria 
and revising such strain collections is currently ongoing 
and will be a key element in developing and evaluating 
new protein based vaccines in the time to come [35].
Conclusions
Where applied with routine childhood programs + catch-
up in children and adolescents, meningococcal C conju-
gate vaccines have demonstrated high effectiveness in 
preventing invasive disease in both vaccinated and in non-
immunized subjects, thanks to the herd immunity effect.
A new tetravalent (ACWY) conjugate vaccine is now 
available, the use of which in place of the conjugate C 
dose for adolescent and for children over 2 years of age 
should be considered. 
In Italy the administration of a single MCC dose to 11-18 
years adolescents is now recommended in subjects who 
have not been vaccinated in childhood. The objectives 
of the National Prevention Plan 2012-2014 for menin-
gococcal vaccination are: achieving and maintaining 
in newborns and adolescents (11-18 years) vaccination 
coverage ≥ 95%. Targets are still too far to be reached.
In Italy vaccination policies are characterized by high 
regional heterogeneity. Some Regions offer the same 
vaccination free to all newborns and others only to risk 
groups, besides differences within the same Region 
can be observed, for different behaviors of each Local 
Health Unit. According to our result MCC vaccination 
was effective in Tuscany to prevent Men C disease and 
all Italian Regions should introduce this vaccination in 
order to protect their population. To date, a universal 
vaccination programme is implemented free of charge 
in 17 out of 21 Regions (81%) for meningococcal C 
vaccine. Nine of these Regions also provide immu-
nization to susceptible adolescents. Italian Regions 
are moving towards a common vaccination strategy 
concerning pneumococcal and meningococcal C vac-
cine [36].
It is expected that incoming meningococcal B vaccines 
are tested with 2+1 schedule, now increasingly common 
in European countries for invasive bacterial diseases; 
their inclusion in the already crowded childhood im-
munization schedule should be carefully evaluated in its 
coverage implications and acceptability.
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